Illumina, Inc. (ILMN)
NASDAQ: ILMN · Real-Time Price · USD
119.93
-2.05 (-1.68%)
At close: Nov 13, 2025, 4:00 PM EST
117.09
-2.84 (-2.37%)
Pre-market: Nov 14, 2025, 8:38 AM EST
Illumina Revenue
Illumina had revenue of $1.08B in the quarter ending September 28, 2025, with 0.37% growth. This brings the company's revenue in the last twelve months to $4.29B, down -2.32% year-over-year. In the year 2024, Illumina had annual revenue of $4.37B, down -2.93%.
Revenue (ttm)
$4.29B
Revenue Growth
-2.32%
P/S Ratio
4.38
Revenue / Employee
$413,500
Employees
10,370
Market Cap
18.33B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 29, 2024 | 4.37B | -132.00M | -2.93% |
| Dec 31, 2023 | 4.50B | -80.00M | -1.75% |
| Jan 1, 2023 | 4.58B | 58.00M | 1.28% |
| Jan 2, 2022 | 4.53B | 1.29B | 39.73% |
| Jan 3, 2021 | 3.24B | -304.00M | -8.58% |
| Dec 29, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 3, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ILMN News
- 1 day ago - Illumina whole-genome sequencing provides greater insight into genetic signals behind common diseases--according to Nature study - PRNewsWire
- 2 days ago - Illumina To Webcast Upcoming Investor Conference - PRNewsWire
- 3 days ago - Illumina® Protein Prep delivers groundbreaking precision in NGS proteomics for more than 40 customers, ranging from academic institutions to large national biobanks - PRNewsWire
- 8 days ago - Illumina Responds to Positive Updates from Chinese Ministry of Commerce - PRNewsWire
- 13 days ago - DNA Sequencing Firm Illumina Sees Strong Clinical Market Momentum, Stock Soars - Benzinga
- 14 days ago - Illumina, Inc. (ILMN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 14 days ago - Illumina Reports Financial Results for Third Quarter of Fiscal Year 2025 - PRNewsWire
- 23 days ago - Illumina: Innovation Outweighs Short-Term Risks - A Long-Term Buy Ahead Of Q3 Earnings - Seeking Alpha